| Geld/Brief | 2,28 $ / 2,55 $ |
| Spread | +11,84% |
| Schluss Vortag | 2,57 $ |
| Gehandelte Stücke | 25.889 |
| Tagesvolumen Vortag | 95.586,13 $ |
| Tagestief 2,53 $ Tageshoch 2,56 $ | |
| 52W-Tief 0,51 $ 52W-Hoch 3,21 $ | |
| Jahrestief 2,31 $ Jahreshoch 2,655 $ | |
| Umsatz in Mio. | 47,98 $ |
| Operatives Ergebnis (EBIT) in Mio. | -73,36 $ |
| Jahresüberschuss in Mio. | -68,57 $ |
| Umsatz je Aktie | 0,89 $ |
| Gewinn je Aktie | -1,27 $ |
| Gewinnrendite | -148,66% |
| Umsatzrendite | - |
| Return on Investment | -62,03% |
| Marktkapitalisierung in Mio. | 55,66 $ |
| KGV (Kurs/Gewinn) | -0,81 |
| KBV (Kurs/Buchwert) | 1,21 |
| KUV (Kurs/Umsatz) | 1,16 |
| Eigenkapitalrendite | - |
| Eigenkapitalquote | +41,72% |
| Handelsplatz | Letzter | Änderung | Vortag | Zeit | |
|---|---|---|---|---|---|
| Düsseldorf | 2,16 € | +0,93% | 2,14 € | 09.01.26 | |
| Frankfurt | 2,05 € | -2,38% | 2,10 € | 09.01.26 | |
| München | 2,18 € | 0 % | 2,18 € | 09.01.26 | |
| Stuttgart | 2,155 € | -0,69% | 2,17 € | 09.01.26 | |
| L&S RT | 2,17 € | -1,36% | 2,20 € | 09.01.26 | |
| NYSE | 2,555 $ | -0,39% | 2,565 $ | 09.01.26 | |
| Nasdaq | 2,56 $ | -0,39% | 2,57 $ | 09.01.26 | |
| AMEX | 2,55 $ | -0,20% | 2,555 $ | 08.01.26 | |
| Tradegate | 2,225 € | +1,37% | 2,195 € | 07.01.26 | |
| Quotrix | 2,21 € | -0,45% | 2,22 € | 09.01.26 | |
| Gettex | 2,185 € | +0,23% | 2,18 € | 09.01.26 | |
| Datum | Kurs | Volumen |
|---|---|---|
| 09.01.26 | 2,56 | 42.339 |
| 08.01.26 | 2,57 | 97 T |
| 07.01.26 | 2,60 | 165 T |
| 06.01.26 | 2,50 | 61 T |
| 05.01.26 | 2,435 | 89 T |
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Woche | 2,35 $ | +8,94% |
| 1 Monat | 2,33 $ | +9,87% |
| 6 Monate | 3,04 $ | -15,79% |
| 1 Jahr | 1,00 $ | +156,00% |
| 5 Jahre | 16,72 $ | -84,69% |
| Marktkapitalisierung | 110,19 Mio. € |
| Aktienanzahl | 55,91 Mio. |
| Streubesitz | 59,58% |
| Währung | EUR |
| Land | USA |
| Sektor | Gesundheit |
| Branche | Biotechnologie |
| Aktientyp | Stammaktie |
| +4,20% | Pfizer Inc |
| +3,47% | Vanguard Group Inc |
| +2,87% | Anson Funds Management LP |
| +1,58% | Alphabet Inc |
| +1,48% | Renaissance Technologies Corp |
| +0,91% | Schonfeld Strategic Advisors LLC |
| +0,91% | Geode Capital Management, LLC |
| +0,77% | BlackRock Inc |
| +0,55% | MONIMUS CAPITAL MANAGEMENT, LP |
| +0,42% | The Informed Momentum Company (formerly EAM Investors) |
| +0,28% | Stonepine Capital Management Llc |
| +0,27% | State Street Corp |
| +0,27% | Ionic Capital Management LLC |
| +0,26% | ADAR1 Capital Management LLC |
| +0,20% | Bridgeway Capital Management, LLC |
| +0,18% | Citadel Advisors Llc |
| +0,18% | Northern Trust Corp |
| +0,12% | Susquehanna International Group, LLP |
| +0,06% | XTX Topco Ltd |
| +0,06% | Axxcess Wealth Management, LLC |
| +21,38% | Weitere |
| +59,58% | Streubesitz |
Zahlen für Q4/22
- Initiated proof-of-concept Phase 2 trial of SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD); top line data expected in 1H 2024
- to fund its operating expenses and capital expenditure requirements beyond 2024
https://s3.amazonaws.com/b2icontent.irpass.cc/2748/rl117181.pdf